Refractory Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma
11 clinical trials · Condition
◉ Watch Refractory Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma
| Record | Firm | Date |
|---|---|---|
| ALX148, Rituximab and Lenalidomide for the Treatment of Indolent and Aggressive B-cell Non-Hodgkin Lymphoma (NCT05025800) | M.D. Anderson Cancer Center | 2021-10-13 |
| Anakinra for the Reduction of CAR-T Toxicity in Patients With Relapsed or Refractory Large B-cell Lymphoma (NCT04432506) | M.D. Anderson Cancer Center | 2020-07-27 |
| Cardiovascular Events Among Adults Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma Treated With Standard of Care Chimeric Antigen Receptor T Cell Therapy (NCT04870853) | M.D. Anderson Cancer Center | 2020-04-02 |
| Anakinra in Preventing Severe Chimeric Antigen Receptor T-Cell Related Encephalopathy Syndrome in Patients With Recurrent or Refractory Large B-cell Lymphoma (NCT04205838) | Jonsson Comprehensive Cancer Center | 2020-03-04 |
| Pembrolizumab and External Beam Radiation Therapy in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma (NCT03210662) | M.D. Anderson Cancer Center | 2018-02-01 |
Track Refractory Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma automatically
Every clearance here is in the API, with alerts when new ones post.